10.2. priapism special situations. 10.2.1. stuttering (recurrent intermittent) priapism stuttering priapism, also termed intermittent recurrent priapism, distinct condition characterised repetitive painful episodes prolonged erections. erections self-limiting intervening periods detumescence . analogous repeated episodes ischaemic priapism. stuttering priapism duration erections generally shorter ischaemic priapism . frequency and/or duration episodes variable single episode sometimes progress prolonged ischaemic priapism. robust epidemiological studies stuttering priapism lacking . however, recurrent priapism episodes common men scd (42-64%) adolescents young men incidence priapism 35%, 72% history stuttering priapism . aetiology stuttering priapism similar ischaemic priapism. whilst scd common cause, idiopathic cases cases due neurological disorder reported. men acute ischaemic priapism, especially prolonged (for four hours) risk developing stuttering priapism . several studies proposed alternative mechanisms stuttering priapism including inflammation, cellular adhesion, metabolism, vascular reactivity coagulation [1336,1352,1395,1437,1442-1445]. although debated, androgens also observed association priapism . therefore, one options treatment stuttering priapism reduce serum testosterone levels hypogonadal levels, suppresses androgen-associated mechanisms believed involved triggering recurrent priapism. 10.2.1.1. diagnostic evaluation history, physical examination, laboratory testing penile imaging follow principals ischaemic priapism. stuttering priapism history recurrent episodes prolonged erections. episodes occur several daily isolated incidents every months, continuously followed incident-free periods, unknown duration, even months years . onset priapic episodes usually occurs sleep detumescence occur upon waking. episodes painful may reason patient first seeks medical attention. erections painful penis rigid ischaemic priapism, duration events usually shorter. erections penis usually normal, cases signs fibrosis found. rarely, penis may become enlarged, condition known megalo-phallus. recommendations diagnosis stuttering priapism described section 10.1.2.5 10.2.1.2. disease management primary goal management patients stuttering priapism prevention episodes limiting chances developing prolonged ischaemic priapism refractory conventional treatment options. cases, stuttering priapism managed pharmacological treatment. management acute episode similar ischaemic priapism; aspiration/irrigation combination intracavernous injections α-adrenergic agonists. 10.2.1.2.1.α-adrenergic agonists studies oral α-adrenergic agonists suggested prophylactic benefit daily treatment agents . adverse effects include tachycardia palpitations. pseudoephedrine widely used oral decongestant first-line treatment option stuttering priapism . however, effect corporal smooth muscle fully understood. etilephrine used successfully prevent stuttering priapism caused scd. usually taken orally doses 5-10 mg daily, response rates 72% [1449-1451]. placebo-controlled rct comparing medical prophylaxis etilephrine ephedrine, difference efficacy two drugs . 10.2.1.2.2. hormonal manipulations circulating testosterone aim hormonal manipulation down-regulate circulating testosterone levels suppress action androgens penile erection . achieved gnrh agonists antagonists, antiandrogens oestrogens . potential adverse effects may include hot flushes, gynaecomastia, ed, loss libido, asthenia. approaches similar efficacy profile potential cardiovascular toxicity oestrogens limits clinical use. alternative endocrine approaches used success include 5-α-reductase inhibitors ketoconazole; anti-fungal agent reduces adrenal testicular androgen production . duration hormonal treatment effective suppression recurrent priapism problematic. possible draw conclusions dose, duration treatment efficacy. caution strongly advised prescribing hormonal treatments pre-pubertal boys adolescents, specialist advice paediatric endocrinologists sought. likewise, hormonal agents contraceptive effect interfere normal sexual maturation spermatogenesis affect fertility. therefore, men trying partner conceive comprehensively counselled using hormonal treatment. moreover, sperm cryopreservation may considered mitigate potential effects anti-androgen therapy fertility. 10.2.1.2.3. digoxin digoxin cardiac glycoside positive inotrope used treat congestive heart failure. digoxin regulates smooth muscle tone several different pathways leading penile detumescence . use maintenance digoxin doses (0.25-0.5 mg/daily) idiopathic stuttering priapism reduces number hospital visits improves qol . small, clinical, double-blind, placebo-controlled study, digoxin decreased sexual desire excitement concomitant reduction penile rigidity, regardless significant change plasma levels testosterone, oestrogens lh . adverse effects include decreased libido, anorexia, nausea, vomiting, confusion, blurred vision, headache, gynaecomastia, rash arrhythmia. 10.2.1.2.4. terbutaline terbutaline used prevent stuttering priapism detumescence rates 36% patients alprostadil-induced priapism . rct (n = 68) patients pharmacologically-induced priapism, demonstrated detumescence 42% terbutaline-treated group compared 15% placebo-treated group . adverse effects include nervousness, shakiness, drowsiness, palpitations, headache, dizziness, hot flushes, nausea weakness. 10.2.1.2.5. gabapentin gabapentin anticonvulsant, antinociceptive anxiolytic properties widely used analgesic anti-epileptic agent. proposed mechanism action inhibit voltage-gated calcium channels, attenuates synaptic transmission , reduces testosterone fsh levels . given dose 400 mg, four times daily, 2,400 mg daily, complete penile detumescence occurs, subsequent maintenance administration 300 mg/daily . adverse effects include anorgasmia impaired erectile function. 10.2.1.2.6. baclofen baclofen gamma-aminobutyric acid (gaba) derivative acts muscle relaxant anti-muscle spasm agent. inhibit penile erection ejaculation gaba activity prevents recurrent reflexogenic erections prolonged erections neurological diseases . oral baclofen little efficacy usually used stuttering priapism intrathecal administration effective [1395,1461-1463]. adverse effects include drowsiness, confusion, dizziness, weakness, fatigue, headache, hypotension nausea. 10.2.1.2.7. hydroxyurea hydroxyurea blocks synthesis deoxyribonucleic acid (dna) inhibiting ribonucleotide reductase, effect arresting cells s-phase . hydroxyurea established treatment ameliorating scd improving life expectancy . patients recurrent priapism, limited evidence suggest prophylactic role hydroxyurea . adverse effects include oligo-zoospermia leg ulcers. 10.2.1.2.8. phosphodiesterase type 5 inhibitors low doses pde5is paradoxical effect alleviating preventing stuttering priapism; mainly patients idiopathic scd-associated priapism [1351,1395,1443,1467-1471]. important remember therapy started penis flaccid state acute episode. delay one week treatment effective. reported impairments male sexual function. 10.2.1.2.9. intracavernosal injections patients stuttering priapism, started systemic treatment prevent recurrence unwanted erections, may see therapeutic benefits immediately temporarily require intracavernous self-injections home sympathomimetic agents . commonly used drugs phenylephrine etilephrine . tissue plasminogen activator (tpa) secreted serine protease converts pro-enzyme plasminogen plasmin, acts fibrinolytic enzyme. limited clinical data suggested single intracavernous injection tpa successfully treat patients recalcitrant priapism . mild bleeding commonly observed adverse effect. 10.2.1.2.10. penile prosthesis patients medically refractory stuttering priapism require frequent visits emergency department always risk major ischaemic episode, mitigated insertion penile prosthesis . nevertheless, penile prosthesis preventing stuttering priapism offered medical treatment penile prosthesis performed carefully selected patients last resort . patients permanent ed due stuttering priapism, medical treatments ed used cautiously risk inducing ischaemic episode penile prosthesis considered . 10.2.1.3. summary evidence recommendations treatment stuttering priapism summary evidencelethe primary goal management patients stuttering priapism prevention future episodes, generally achieved pharmacologically.2bhormonal therapy gnrh agonists antagonists antiandrogens able reduce risk recurrent priapism episodes although associated adverse events (hot flushes, gynaecomastia, ed, loss libido, asthenia infertility)3phosphodiesterase type 5 inhibitors paradoxical effect alleviating preventing stuttering priapism, mainly patients idiopathic sickle cell disease-associated priapism.3the evidence systemic drugs (digoxin, α-adrenergic agonists, baclofen, gabapentin terbutaline, hydroxyurea) limited.3 recommendationsstrength ratingmanage acute episode according treatment recommendations ischaemic priapism (section 10.1.4).stronguse hormonal therapies (mainly gonadotropin-receptor hormone agonists antagonists) and/or anti-androgens prevention future episodes patients frequent relapses. use sexual maturation reached.weakinitiate treatment phosphodiesterase type 5 inhibitors penis flaccid state.weakuse digoxin, α-adrenergic agonists, baclofen, gabapentin terbutaline patients frequent uncontrolled relapses.weakuse intracavernous self-injections sympathomimetic drugs home treatment acute episodes interim basis ischaemic priapism alleviated.weak 10.2.1.4. follow-up follow-up stuttering priapism includes history clinical examination assess efficacy treatment preventing alleviating erectile events well assessing erectile function penile fibrosis. 10.2.2. priapism children classification priapism children similar adults. addition ischaemic, stuttering non-ischaemic priapism, fourth type, neonatal priapism also described . priapism children considered rare data prevalence exist. sickle cell disease major cause priapism children, followed leukaemia (10%), trauma (10%), idiopathic causes (19%) drugs (5%) . one study showed 25% children experienced scd-related priapism pre-pubertal period . another study revealed 90% men scd first priapism episode age 20 years . priapism children evaluated treated timely manner, untreated ischaemic priapism may lead ed psychosexual disorders adulthood . multi-disciplinary team approach utilised specialist input haematologists paediatric endocrinologists.